In this epidemiological study, we confirmed that the alteration in the HSD3B1 gene that affected the progression of prostate cancer in clinical trials, is associated with increased risk of prostate cancer death in men diagnosed with metastatic disease. This evidence concerns the gene HSD3B1 and metastatic neoplasm.